Back to results
US 11,111,300 B2Granted
Anti PD-L1 antibodies
AssigneeApollomics Inc.
InventorsJiping Zha, Ziyong Sun, Junzhuan Qiu
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antibodies and antigen-binding fragments thereof that bind to PD-L1, and to methods of using such antibodies and antigen-binding fragments. For example, the present invention provides humanized anti-PD-L1 antibodies and methods of use thereof.
Claims31
A method for treating a PD-L1 expressing cancer in a human subject having the PD-L1 expressing cancer, the method comprising administering to the subject an antibody or fragment thereof that binds to PD-L1, wherein the antibody or fragment thereof comprises:
- (i) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 93, 94, and 95, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 96, 97, and 98, respectively;
- (ii) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 81, 82, and 83, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 84, 85, and 86, respectively;
- (iii) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 87, 88, and 89, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 90, 91, and 92, respectively;
- (iv) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 99, 100, and 101, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 102, 103, and 104, respectively;
- (v) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 105, 106, and 107, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 108, 109, and 110, respectively;
- (vi) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 111, 112, and 113, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 114, 115, and 116, respectively;
- (vii) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 117, 118, and 119, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 120, 121, and 122, respectively;
- (viii) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 123, 124, and 125, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 126, 127, and 128, respectively;
- (ix) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 129, 130, and 131, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 132, 133, and 134, respectively;
- or
- (x) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 135, 136, and 137, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 138, 139, and 140, respectively.
28 more elements
A method for reducing PD-L1 expressing tumors or inhibiting the growth of PD-L1 expressing tumor cells in a subject, the method comprising administering to the subject an antibody or fragment thereof that binds to PD-L1, wherein the antibody or fragment thereof comprises:
- (i) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 93, 94, and 95, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 96, 97, and 98, respectively;
- (ii) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 81, 82, and 83, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 84, 85, and 86, respectively;
- (iii) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 87, 88, and 89, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 90, 91, and 92, respectively;
- (iv) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 99, 100, and 101, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 102, 103, and 104, respectively;
- (v) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 105, 106, and 107, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 108, 109, and 110, respectively;
- (vi) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 111, 112, and 113, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 114, 115, and 116, respectively;
- (vii) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 117, 118, and 119, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 120, 121, and 122, respectively;
- (viii) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 123, 124, and 125, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 126, 127, and 128, respectively;
- (ix) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 129, 130, and 131, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 132, 133, and 134, respectively;
- or
- (x) a heavy chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 135, 136, and 137, respectively, and a light chain CDR1, CDR2, and CDR3 sequence comprising SEQ ID NO:
- 138, 139, and 140, respectively.
28 more elements
Dependencies are inferred from the claim text.